Controlled-release theophylline and proxyphylline in asthmatics : a comparative study
In a short-term study, a new sustained-release preparation of proxyphylline (2400 mg/day) was compared to theophylline (800 mg/day) and placebo. A double-blind crossover design was used, and 10 adult asthmatics participated. No significant differences were found between the treatments with regard to...
| Veröffentlicht in: | Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC). - 1995. - 3(1984), 9 vom: 14., Seite 626-30 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , |
| Format: | Aufsatz |
| Sprache: | English |
| Veröffentlicht: |
1984
|
| Zugriff auf das übergeordnete Werk: | Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC) |
| Schlagworte: | Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Delayed-Action Preparations proxyphylline 13G1DMN4P0 Aminophylline 27Y3KJK423 Theophylline |
| Zusammenfassung: | In a short-term study, a new sustained-release preparation of proxyphylline (2400 mg/day) was compared to theophylline (800 mg/day) and placebo. A double-blind crossover design was used, and 10 adult asthmatics participated. No significant differences were found between the treatments with regard to relief of asthma symptoms, need for additional medication or incidence and intensity of side-effects. In the placebo period, morning peak-flow was significantly lower compared to active treatment periods |
|---|---|
| Beschreibung: | Date Completed 29.06.1984 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |